AstraZeneca’s Truqap Demonstrates Phase 3 Success in Prostate Cancer
AstraZeneca’s Truqap (capivasertib) has achieved a significant milestone in the treatment of prostate cancer. Results from the CAPItello-281 Phase III
Read moreAstraZeneca’s Truqap (capivasertib) has achieved a significant milestone in the treatment of prostate cancer. Results from the CAPItello-281 Phase III
Read moreAOP Orphan Pharmaceuticals GmbH (AOP Health), in collaboration with Leukos Biotech, has reached a significant milestone in cancer therapy. The
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read moreA research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip
Read moreThe 3-D Life RGD Peptide is a highly purified peptide designed specifically to enhance cell adhesion within 3-D hydrogel matrices.
Read moreCellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreBritish pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab
Read moreIn a strategic move to bolster its global supply of antibody-drug conjugates (ADCs), AstraZeneca has announced the development of a
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read more